Colon-specific delivery of curcumin by exploiting Eudragit-decorated chitosan nanoparticles in vitro and in vivo

The aim of present investigation was to prepare chitosan (CS) nanoparticles (NPs) and to study the targeting ability of Eudragit S 100 (ES)-coated chitosan nanoparticles (ES-CS-NPs) in comparison with CS-NPs; both loaded with curcumin (CU); to colon, when administered orally, by restricting the size of formulation up to few nanometers and exploiting the pH sensitivity of ES. The CU-loaded CS-NPs (CS-NPs-CU) have been prepared by ionic gelation method. The coating of ES on CS-NPs-CU (ES-CS-NPs-CU) was performed by oil-in-oil solvent evaporation method using coat:core ratio (2:1). The cross-linking of CS with tri poly phosphate during the preparation of CS-NPs has been confirmed by FTIR. CS-NPs-CU and ES-CS-NPs-CU were evaluated for particle size, their size distribution, percentage drug entrapment, and in vitro drug release study. CS-NPs-CU has an average size 173 ± 4.5 nm and poly dispersity index (PDI) 0.16, whereas ES-CS-NPs-CU shows average size 236 ± 3.2 nm and PDI 0.22. Surface morphology of prepared NPs was confirmed by scanning electron microscopy and transmission electron microscopy. The release profile reveals that the ES coating on the ES-CS-NPs-CU protects the release of CU in upper gastrointestinal tract while maximum release of CU occurred in simulated colonic fluids of pH 6.8. There was no major difference in cell viability between ES-CS-NPs-CU and CS-NPs-CU when they were exposed to Caco-2 cells at all equivalent concentrations. The in vivo uptake studies revealed preferential uptake of ES-CS-NPs-CU in the colon. The significantly higher (P < 0.01) AUC0–∞ has been observed in case of ES-CS-NPs-CU as compared to CU and CS-NPs-CU representing that ES-CS-NPs-CU was more bioavailable. These results demonstrated that ES-CS-NPs-CU may be useful as potential delivery system for treatment of colon cancer.